department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Nourianz · pharmadog

pharmadog
drugs
Nourianz

drug

patient view →

istradefylline

Marketedupdated 2mo ago

by Kyowa Hakko USA Inc

Approved

community read0 votes

indications

investigational

NSCLCParkinson's Disease

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Nourianz

generic

istradefylline

indication

Parkinson's Disease

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 5, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jan 28, 2028formulationUS 77279931.6y
Jan 28, 2028formulationUS 77279931.6y
Sep 5, 2027formulationUS 83182011.2y
Sep 5, 2027formulationUS 83182011.2y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying istradefylline

—Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.terminatedn=8
phase2Istradefylline for Parkinson Disease With Cognitive Impairmentcompletedn=15
phase4Istradefylline Effect Protocol on Parkinson's Disease Tremorcompletedn=27
phase3An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001terminatedn=504
phase1Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefyllinecompletedn=20
phase1A Study to Evaluate Abuse Potential of Istradefyllinecompletedn=42
phase3A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopacompletedn=230
phase3A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopacompletedn=580

more trials →